All In MedTech

Device Trial Radar · NCT02857816

PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB

PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation (PTNM) System in Patients With OAB

Last checked: Nov 20, 2026Latest source record: Jan 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

154

Actual

Start

Sep 2016

Primary completion

Nov 21, 2017

Study completion Nov 21, 2017

Sponsor

Lead sponsor
MedtronicNeuroNot on our public-company list
Sponsor type
Industry
First posted
Aug 5, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the NURO system for the treatment of OAB in drug naïve patients.

Conditions

  • Overactive Bladder

Interventions

  • NURO System PTNM TherapyDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Number of Urinary Urge Incontinence (UUI) Episodes Per Day After the 12th PTNM Therapy Sessions From BaselineTime frame: 12 Weeks

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Pinellas Urology, Inc.

    St. Petersburg, Florida

  • NorthShore University Health System

    Evanston, Illinois

  • Mount Auburn Hospital

    Cambridge, Massachusetts

8 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.